The remaining 30% of breast cancers represent either the human epidermal growth factor receptor (HER2)-enriched subtype or triple negative breast cancers (TNBC), so named as they lack ER, PR, and HER2 expression. This evidence concerns the gene ESR1 and breast cancer.